Revolutionary AI-powered blood test for cancer enters NHS trials

A highly accurate blood test that uses artificial intelligence to detect multiple cancers from just a few drops of blood is now entering clinical trials across the UK’s National Health Service.

A groundbreaking AI-driven blood test known as miONCO-Dx is set to begin clinical trials with the UK’s National Health Service (NHS), potentially transforming how cancer is detected and diagnosed.

Developed to identify up to 12 of the most common and deadly cancers — including bowel, breast, lung, ovarian, and pancreatic — the test boasts a reported accuracy rate of over 99%, according to Kazinform.

The new trial will involve 8,000 patients and builds on data from more than 20,000 individuals. The UK government has allocated £2.4 million in funding to support the project, which is seen as a potential breakthrough in cancer diagnostics.

Cancer remains a major global health threat, and early detection is critical. In the United States alone, it is the second leading cause of death, with more than 600,000 fatalities annually. Experts emphasize that survival rates can dramatically improve with early diagnosis — nine out of ten bowel cancer patients survive if detected at stage one, compared to just one in ten at stage four.

If successful, the miONCO-Dx test could ease pressure on overburdened healthcare systems by providing a fast, non-invasive, and highly accurate alternative to traditional diagnostic methods.

Copied